A new personalized liquid biopsy assay named MRD4U offers unprecedented sensitivity for monitoring central nervous system tumors in children. Detailed in BMC Cancer, this genomic tool allows earlier detection and dynamic assessment of residual disease, potentially transforming pediatric neuro-oncology diagnostics and therapeutic management. This advance exemplifies tailored molecular technologies improving precision medicine for challenging pediatric malignancies.